NOT FOR DISTRIBUTION
Header cover image

China Resources Pharmaceutical Group

Market Cap

HK$31.9b

Last Updated

2021/04/16 10:33 UTC

Data Sources

Company Financials +

Executive Summary

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in the People’s Republic of China. More Details


Snowflake Analysis

Excellent balance sheet and good value.


Similar Companies

Share Price & News

How has China Resources Pharmaceutical Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 3320 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 3320's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

3.3%

3320

-1.5%

HK Pharmaceuticals

0.7%

HK Market


1 Year Return

5.4%

3320

18.8%

HK Pharmaceuticals

28.0%

HK Market

Return vs Industry: 3320 underperformed the Hong Kong Pharmaceuticals industry which returned 20.3% over the past year.

Return vs Market: 3320 underperformed the Hong Kong Market which returned 28.5% over the past year.


Shareholder returns

3320IndustryMarket
7 Day3.3%-1.5%0.7%
30 Day-12.6%-4.6%-1.2%
90 Day26.8%6.2%1.8%
1 Year8.1%5.4%20.5%18.8%33.4%28.0%
3 Year-49.5%-51.9%-11.0%-16.0%8.1%-3.9%
5 Yearn/a94.1%75.5%56.5%28.9%

Long-Term Price Volatility Vs. Market

How volatile is China Resources Pharmaceutical Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is China Resources Pharmaceutical Group undervalued compared to its fair value and its price relative to the market?

3.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 3320 (HK$5.07) is trading below our estimate of fair value (HK$5.23)

Significantly Below Fair Value: 3320 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 3320 is good value based on its PE Ratio (9.7x) compared to the HK Pharmaceuticals industry average (12.4x).

PE vs Market: 3320 is good value based on its PE Ratio (9.7x) compared to the Hong Kong market (11.7x).


Price to Earnings Growth Ratio

PEG Ratio: 3320 is poor value based on its PEG Ratio (1.7x)


Price to Book Ratio

PB vs Industry: 3320 is good value based on its PB Ratio (0.7x) compared to the HK Pharmaceuticals industry average (1.3x).


Future Growth

How is China Resources Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

5.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3320's forecast earnings growth (5.7% per year) is above the savings rate (1.5%).

Earnings vs Market: 3320's earnings (5.7% per year) are forecast to grow slower than the Hong Kong market (18.4% per year).

High Growth Earnings: 3320's earnings are forecast to grow, but not significantly.

Revenue vs Market: 3320's revenue (7.6% per year) is forecast to grow slower than the Hong Kong market (13.3% per year).

High Growth Revenue: 3320's revenue (7.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 3320's Return on Equity is forecast to be low in 3 years time (7.3%).


Past Performance

How has China Resources Pharmaceutical Group performed over the past 5 years?

6.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 3320 has high quality earnings.

Growing Profit Margin: 3320's current net profit margins (1.6%) are higher than last year (1.6%).


Past Earnings Growth Analysis

Earnings Trend: 3320's earnings have grown by 6% per year over the past 5 years.

Accelerating Growth: 3320's earnings growth over the past year (0.4%) is below its 5-year average (6% per year).

Earnings vs Industry: 3320 earnings growth over the past year (0.4%) underperformed the Pharmaceuticals industry 2.7%.


Return on Equity

High ROE: 3320's Return on Equity (6.7%) is considered low.


Financial Health

How is China Resources Pharmaceutical Group's financial position?


Financial Position Analysis

Short Term Liabilities: 3320's short term assets (HK$147.1B) exceed its short term liabilities (HK$122.6B).

Long Term Liabilities: 3320's short term assets (HK$147.1B) exceed its long term liabilities (HK$6.7B).


Debt to Equity History and Analysis

Debt Level: 3320's debt to equity ratio (67.9%) is considered high.

Reducing Debt: 3320's debt to equity ratio has reduced from 94.6% to 67.9% over the past 5 years.

Debt Coverage: 3320's debt is well covered by operating cash flow (21.4%).

Interest Coverage: 3320's interest payments on its debt are well covered by EBIT (3.8x coverage).


Balance Sheet


Dividend

What is China Resources Pharmaceutical Group current dividend yield, its reliability and sustainability?

2.37%

Current Dividend Yield


Upcoming Dividend Payment

TodayApr 17 2021Ex Dividend DateJun 02 2021Dividend Pay DateJun 23 202121 days from Ex DividendBuy in the next 46 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 3320's dividend (2.37%) is higher than the bottom 25% of dividend payers in the Hong Kong market (1.96%).

High Dividend: 3320's dividend (2.37%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.97%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 3320 has been paying a dividend for less than 10 years.

Growing Dividend: 3320's dividend payments have increased, but the company has only paid a dividend for 4 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (22.9%), 3320's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 3320's dividends in 3 years are forecast to be well covered by earnings (21.8% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Yuewei Han (52 yo)

1.5yrs

Tenure

HK$518,000

Compensation

Mr. Yuewei Han serves as Chief Executive Officer and Executive Director at China Resources Pharmaceutical Group Limited since October 22, 2019. He has been Chief Executive Officer of China Resources Health...


CEO Compensation Analysis

Compensation vs Market: Yuewei's total compensation ($USD66.69K) is below average for companies of similar size in the Hong Kong market ($USD720.24K).

Compensation vs Earnings: Insufficient data to compare Yuewei's compensation with company performance.


Leadership Team

Experienced Management: 3320's management team is considered experienced (4.6 years average tenure).


Board Members

Experienced Board: 3320's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

China Resources Pharmaceutical Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China Resources Pharmaceutical Group Limited
  • Ticker: 3320
  • Exchange: SEHK
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$31.855b
  • Shares outstanding: 6.28b
  • Website: https://www.crpharm.com

Number of Employees


Location

  • China Resources Pharmaceutical Group Limited
  • China Resources Building
  • 41st Floor
  • Wan Chai
  • Hong Kong

Listings


Biography

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products i...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/16 10:33
End of Day Share Price2021/04/16 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.